{"entity":{"id":"nct07188246","kind":"trial","name":"Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast Cancer","aka":["BRINK"],"tldr":"A phase 2 trial of pembrolizumab in triple-negative breast cancer, run by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's, now recruiting.","summary":"Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast Cancer is a phase 2, interventional study registered as NCT07188246 by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's, with a registry enrolment figure of 40 participants, started 2026-01-19 and due to reach its primary completion in 2027-07. Interventions recorded: Radiation; Pembrolizumab (KEYTRUDA®). Conditions listed: Breast Cancer; Breast Cancer Stage II; Breast Cancer Stage III; Breast Cancer Invasive; Breast Cancer Triple Negative. Triple-negative eligibility wording from the registry: \"Stage IIA is eligible for triple negative and HER2+ breast cancers\". Sites: Canada. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07188246","url":"https://clinicaltrials.gov/study/NCT07188246"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07188246","phase":"2","setting":"A Trial of Neoadjuvant, Hypofractionated Radiation, With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy, in Stage 3 or High-risk Stage 2 Breast Cancer","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","enrolled":40,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07188246/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}